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Introduction: Febrile neutropaenia is a frequently occurring and occasionally life-threaten-
ing complication of treatment for childhood cancer, yet many children are aggressively
over-treated. We aimed to undertake a systematic review and meta-analysis to summarise
evidence on the discriminatory ability and predictive accuracy of clinical decision rules
(CDR) of risk stratification in febrile neutropaenic episodes.
Methods: The review was conducted in accordance with Centre for Reviews and Dissemina-
tion methods, using random effects models to undertake meta-analysis. It was registered
with the HTA Registry of systematic reviews, CRD32009100453.
Results: We found 20 studies describing 16 different CDR assessed in 8388 episodes of FNP.
No study compared different approaches and only one CDR had been subject to testing
across multiple datasets. This review cannot conclude that any system is more effective
or reliable than any other.
Conclusion: To maximise the value of the information already collected by these and other
cohorts of children with febrile neutropaenia, an individual-patient-data (IPD) meta-anal-
ysis is required to develop and test new and existing CDR to improve stratification and opti-
mise therapy.
 2010 Elsevier Ltd. Open access under CC BY license.1. Introduction
Children undergoing treatment for malignancy have an
excellent chance of survival, with overall rates approaching
75%.1 In most cases, children who die following treatment
for cancer do so of their disease, but despite huge improve-
ments in supportive care, around 16% of deaths within
5 years of diagnosis are due to the complications of ther-
apy.2,3 One such life-threatening complication in immuno-
compromised children remains infection, frequently
presenting as the occurrence of fever with neutropaenia.4
A robust risk stratification model which reliably predicted; fax: +44 1904 321041.
lips).
C BY license.those children at very low risk of having a significant infec-
tion could result in reduced intensity and/or duration of
hospitalised antibiotic therapy. Those at high risk of com-
plications could be targeted for more aggressive manage-
ment. At present there are many differing policies for the
management of febrile neutropaenia in paediatric prac-
tice5,6 with lack of agreement about how and which clinical
decision rules (CDR), if any, are used.
A clinical decision rule is a tool designed to be used at the
bedside to assist clinical decision making.7 These rules
should be validated by assessing them on a separate popula-
tion; to test both how well the rule differentiates the risk
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estimates of risk within these groups (predictive accuracy).
In adult oncology practice the Multinational Association
for Supportive Care in Cancer (MASCC) risk index8 provides
a CDR to identify patients at low risk of serious medical com-
plications during febrile neutropaenia. The factors identified
included ‘young age’ (<60 years) and no chronic obstructive
airways disease, among other features specific to the disease
type and presentation at each episode, and has been used as
the basis for the out-patient management of fever in low-risk
neutropaenic adult patients.9 The MASCC rule is of very lim-
ited applicability in this group: it did not include children in
its derivation, the age criterion is non-discriminatory, and
chronic airways disease is extremely rare. Accordingly, stud-
ies on children and young people require separate, detailed
examination.
This systematic review aimed to identify, critically ap-
praise and synthesise evidence on the discriminatory ability
and predictive accuracy of existing CDRs in febrile neutropae-
nic episodes in children and young people undergoing treat-
ment for malignant disease.2. Materials and methods
The review was conducted in accordance with ‘Systematic re-
views: CRD’s guidance for undertaking reviews in health
care10 and registered on the HTA Registry of systematic re-
views: CRD32009100453. It sought studies which aimed to de-
rive or validate a CDR in children or young people (aged 0–
18 years) presenting with febrile neutropaenia. Both prospec-
tive and retrospective cohorts were included, but those using
a case–control (‘two-gate’) approach were excluded as these
have been previously shown to exaggerate diagnostic accu-
racy estimates.11 Studies exclusively addressing the predic-
tion of radiologically confirmed pneumonia are subject to a
separate review [in submission to Arch Dis Child – Still under
consideration].
2.1. Search strategy and selection criteria
An electronic search strategy (seeWeb Appendix 1) was devel-
oped which examined the following databases from their
inception to February 2009:
• MEDLINE
• MEDLINE In-Process and Other Non-Indexed Citations
• EMBASE
• CINAHL
• Cochrane Database of Systematic Reviews (CDSR)
• Database of Abstracts of Reviews of Effects (DARE)
• Health Technology Assessment Database (HTA)
• Cochrane Central Register of Controlled Trials (CENTRAL)
• Conference Proceedings Citation Index - Science (CPCI-S)
• Literatura Latinoamericana y del Caribe en Ciencias de la
Salud (LILACS)
Reference lists of relevant systematic reviews and in-
cluded articles were reviewed for further relevant articles.
Published and unpublished studies were sought and nolanguage restrictions applied. Non-English language studies
were translated. Two reviewers independently screened the
title and abstract of studies for inclusion, and then the full
text of retrieved articles. Disagreements were resolved by
consensus.
2.2. Validity assessment and data extraction
The validity of each study was assessed using 11 of the 14
questions from the QUADAS assessment tool for diagnostic
accuracy studies.12 The QUADAS tool was adapted specifically
for the review,13 omitting questions on ‘time between index
and reference test’, ‘intermediate results’ and ‘explanation
of withdrawals’ (see Web Appendix 2). The CDR and reference
tests are necessarily related, and the design of a CDR means
that ‘intermediate’ results are included in any analysis. The
issue of incomplete data was addressed in the analysis of
the method of derivation or validation, and as such was not
included as a quality criterion.
Data were extracted by one reviewer and checked by the
other. The data extracted included age and sex distribution
of the included participants, geographical location of the
study and participant inclusion/exclusion criteria. The perfor-
mance of the CDR as a 2 * k table (where k refers to the num-
ber of strata described) as well as the methods used to derive
the CDR (where applicable), the variables considered, meth-
ods of statistical analysis and approach to multiple episodes
in individual patients and missing data were also extracted.
2.3. Methods of analysis/synthesis
Quantitative synthesis was undertaken for studies which
tested the same CDR and, where appropriate, was investi-
gated for sources for heterogeneity.
For dichotomous test data, analyses were attemptedwith a
bivariate model (using ‘metandi’ in STATA1014). For tests with
very small numbers of studies to pool (n 6 4) fitting a bivariate
model is problematic as the procedure frequently fails to con-
verge. In these cases, a univariate approach was used (pooling
sensitivity and specificity separately).15
For tests where three-level (low, medium and high risk) re-
sults were produced, an approach based on a previous meta-
analysis of three-level CDR results was used.16 This random-
effects meta-analysis was undertaken using WinBUGS
1.4.317 to estimate the proportions of individuals classified
as low, medium or high risk in the bacteraemic and non-bac-
teraemic groups. As an extension to this method, bivariate
random effects were applied to the calculation of each pro-
portion. Data from studies which used a similar rule but pro-
vided only two of the risk categories (i.e. low versus medium–
high) were also included in this analysis.18 These proportions
were used to calculate likelihood ratios (LR) for each risk cat-
egory and the corresponding 95% credible intervals (CrI).
Heterogeneity between study results was explored
through consideration of study populations, study design,
predictor variables assessed and outcomes chosen, although
the small number of studies in each category limited this ap-
proach. Sensitivity analysis was undertaken by comparing re-
sults when the original (derivation) dataset was included and
excluded.
2952 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 2 9 5 0 –2 9 6 4For those areas where a quantitative synthesis was not
possible, a narrative approach was used.
3. Results
Twenty-one articles reporting on 20 studies19–38 were eligible
for inclusion in the review (see Fig. 1). The studies included
patients from 1month to 23 years old, with a wide range of
malignancies, and a total of 7840 episodes of FNP describing
11 outcomes, summarised in 5 clusters: death, critical care
requirement, serious medical complication, significant bacte-
rial infection and bacteraemia (see Table 1). Eight of theseFig. 1 – Flow diagram of sstudies were prospective,25,26,29,30,32,33,36,37 11 were retrospec-
tive19–23,27,28,31,34,35,38 and 1 was a retrospective analysis of
prospectively collected data.24
3.1. Quality assessment
The studies varied in quality. Potential biases due to threats to
independent outcome assessment were present in some
studies (see Web Appendix 3). The applicability of the studies
to specific populations also varied (see Table 1). Thirteen def-
initions of febrile neutropaenia were used, with 12 definitions
of fever and 4 of neutropaenia. However, all definitions aretudy selection process.
Table 1 – Studies of clinical decision rules.
Citation Derivation or
validation study
Study location
(years)
Inclusion criteria Exclusion criteria Total number
of patients
Total number
of episodes
Age of patients Clinical prediction rulea Outcomes
Adcock (1999) Derivation of CDR North Carolina,
USA (1995–1996)
ANC <1000 cells/
mm3, temperature
P38 C, HIV )ve
33 88 Median 5 y (range
1–18 y)
High risk = hypotension/
septic shock, inflamed
central line site, recent high
dose Ara-C
Gram-positive bacteraemia
Alexander (2002) Derivation of CDR Boston, USA
(1994–1995)
ANC 6500/mm3,
temperature
>38.5 C.
Outpatient status
Post stem cell
transplant
104 188 Mean 8.9 y (SD
5.7 y)
Low risk = not AML/Burkitts/
Induction ALL/Progressive-
relapsed with marrow
involvement (‘Anticipated
neutropaenia <7 d’) and no
significant comorbidity
(defined as hypotension,
tachypnea/hypoxia <94%,
new CXR changes, altered
mental status, severe
mucositis, vomiting or
abdominal pain, focal
infection, other clinical
reason for in-patient
treatment)
Bacteraemia
Serious medical complication
Death
High risk = hypotension/
septic shock, inflamed
central line site, recent high
dose Ara-C
Ammann (2003) Derivation of CDR Berne,
Switzerland
(1993–2001)
ANC 6500 cells/
mm3 or
61000 cells/mm3
and falling,
axilliary
temperature
P38.5 C for P2 h,
or once P39 C
Patients with FN
due to malignant
bone marrow
suppression, or
following
myeloablative
therapy
132 364 Not reported Low risk = not AML/Burkitts/
Induction ALL/Progressive-
relapsed with marrow
involvement (‘Anticipated
neutropaenia <7 d’) and no
significant comorbidity
(defined as hypotension,
tachypnea/hypoxia <94%,
new CXR changes, altered
mental status, severe
mucositis, vomiting or
abdominal pain, focal
infection, other clinical
reason for in-patient
treatment)
Severe bacterial infection, (death
from bacterial infection, a positive
culture of normally sterile body fluids,
radiologically proven pneumonia,
clinically unequivocal diagnosis of a
bacterial infection, or CRP > 150 mg/L)
(regression models) Low risk 6 3 factors (model
#2) or 64 factors (model #3).
Risk factors = bone marrow
involvement, absence of
clinical signs of viral
infection, high serum CRP
level, low leucocyte count,
presence of a central venous
catheter, high haemoglobin
level, and Pre-B-cell
leukaemia
Severe bacterial infection (death from
bacterial infection, a positive culture
of normally sterile body fluids,
radiologically proven pneumonia,
clinically unequivocal diagnosis of a
bacterial infection, or CRP > 150 mg/L)
Ammann (2004)
(same population
as Ammann (2003))
Derivation of CDR Additionally,
patients with
established severe
bacterial infection
111 285 Median 6.3 y
(interquartile range
3.2–12.1 y)
Low risk = all of: maximum
temp 6 39.7 C, no
comorbidity requiring
hospitalisation, leucocyte
count > 0.5 · 109/L, and in
partial or complete remission
Bacteraemia
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Table 1 – (Continued)
Citation Derivation or
validation study
Study location
(years)
Inclusion criteria Exclusion criteria Total number
of patients
Total number
of episodes
Age of patients Clinical prediction rulea Outcomes
Gala-Peralta (2005) Validation of CDR Barcelona, Spain
(2002)
ANC 6 500/mm3, ‘fever’
(temperature not defined)
30 62 Mean 8.7 y
(range 1.2–14.7 y)
Low risk 6 2 of: <1 y, poor
bone marrow response
(plt < 75,
ANC < 100),uncontrolled
solid tumour or relapsed
leukaemia, chemotherapy
<10 d earlier, rapid
neutropaenia, cardiac and
renal dysfunction
Positive blood
culture
Hann (1997) Derivation of CDR Multiple centres
across Western
Europe (1986–1994)
ANC 61000 cells/mm3,
temperatureP 38.0 C twice
in <12 h, or onceP 38.5 C, in
an EORTC trial
759 759 Median 8 y No rule described Bacteraemia
Individual features = disease
type, IV line, shock, duration
of granulocytopaenia and
admission temperature
Jones (1996) Derivation of CDR North Carolina,
USA (1987–1993)
ANC <500 cells/mm3, oral
temperatureP 38.0 C
P12 h, or once >38.5 C
None reported, but
‘none of the
children were
undergoing BMT’
127 276 Mean 8 y
(range 2 m to 21 y)
Low risk = ANCP 200,
outpatient at onset, in
remission
Bacteraemia
Clinical infection
Lucas (1996) Derivation of CDR New York, USA
(1990–1992)
ANC <500 cells/mm3 or
<1000 cells/mm3 and falling,
temperatureP 38.0 C P2
occasions in P12 h, or once
P38.5 C. Outpatient status
Received blood
product
transfusions
within 6 h or
cytosine
arabinoside within
2 d of presentation
161 509 Mean 9.2 y
(range 1–18 y)
Low risk = no chills,
hypotension, or a
requirement for fluid
resuscitation at admission
Positive blood
culture
ICU admission
Septic death
Petrelli (1991) Validation of CDR Camargo, Brazil
(1988–1989)
ANC 6 500 cells/mm3,
temperatureP 37.5 C P3
occasions in P24 h, or once
P38.0 C. Outpatient status
Fever associated
with blood product
transfusions or
drugs
146 240 Mean 7.3 y Low risk: patients with solid
tumours and lymphomas
stages I and II. High risk:
patients with leukaemias
and lymphomas stages III
and IV
Positive blood
culture
Riikonen (1993) Derivation of CDR Helsinki, Finland
(1989–1990)
ANC < 200 cells/mm3,
temperature >38.0 C P2
occasions in P4 h, or once
>39.0 C
Antibiotics
(excluding Septrin)
in the preceding
3 weeks
46 91 Range 1–16 y No rule described. No
variables emerged as
significant
Bacteraemia
Focal infection
Suspected sepsis/
fever of unknown
origin
Rojo (2008) Derivation of CDR Santiago, Chile
(2003 –2006)
Episode of febrile
neutropaenia which was
‘low risk’ according to the
PINDA criteria
33 47 Median 5.8 y (1.1–15.7 y) No rule described. No
variables emerged as
significant
‘Unfavourable
outcome’ –
Compound of:
haemodynamic
instability, new
focus if bacterial
infection, 72 h
persistent fever,
unresponsive CRP,
or continuing +ve
blood cultures 72 h
after treatment
2
9
5
4
E
U
R
O
P
E
A
N
JO
U
R
N
A
L
O
F
C
A
N
C
E
R
4
6
(2
0
1
0
)
2
9
5
0
–
2
9
6
4
Table 1 – (Continued)
Citation Derivation or
validation study
Study location
(years)
Inclusion criteria Exclusion criteria Total number
of patients
Total
number of
episodes
Age of patients Clinical prediction rulea Outcomes
Rondinelli (2006) Derivation of CDR San Paulo, Brazil
(2000– 2003)
ANC < 500 cells/mm3 or
61000 cells/mm3 and
falling, temperature
P37.8 C P3 occasions
in P24 h, or once
>38.0 C. First episode
per patient (new or
relapsed disease)
Second or
subsequent
episode. Episodes
in progressive
disease (<6 m from
between
completing
therapy and
relapse). History of
BMT
283 283 Mean 5.2 y Low risk = 2.5–5 points:
Intermediate risk = 5.5– 9
points: High risk = Greater
than 9 points. 4.5 points for:
clinical site of infection; 2.5
points for: no URTI; 2 points
for: CVC; 1 point for:
aged 6 5 y, fever > 38.5 C,
Hb 67 g/dL
‘Serious infectious
complication’ – sepsis,
shock, +ve blood cultures,
infection-related death
Tezcan (2006) Derivation of CDR Antalya, Turkey
(1996–2004)
ANC < 500 cells/mm3 or
<1000 cells/mm3 and
falling, axilliary
temperature P38.0 C
P2 occasions at 4 h
intervals, or once
>38.3 C
Fever that occurred
following
transfusion of
blood and blood
products or
administration of
G-CSF
240 621 Median 6 y (range 1 m to
17 y)
No rule described. Significant
association between
hypotension, uncontrolled
cancer and mortality.
Duration of fever only
independent risk factor for
microbiologically
documented
infection
Death
Clinically suspected
infection
Microbiologically
documented infection
West (2004)
(internally
validated using
bootstrap)
Derivation of CDR California, USA
(1994–1998)
ANC < 500 cells/mm3 or
<1000 cells/mm3 and
falling, axilliary
temperature P38.0 C
P3 occasions in 24 h, or
once P38.5 C, within
21 d of chemotherapy
Induction, relapse
and refractory
disease. Collapse
within 1 h of
admission
143 303 Mean 7.6 y (SD 4.6 y) Very high
risk = temp > 39.5 C and
CRT > 3 s; High
risk = temp > 39.5 C or
CRT > 3s; Low risk = neither
Requirement for critical care
within 24 hs of presentation
(fluid boluses P60 ml/kg,
inotropes or ventilation)
Paganini rule
Paganini (2007) Derivation Multiple centres
across Argentina
(derived 1
institution,
validated in 7
further ones)
(2000–2004)
ANC < 500 cells/mm3 or
<1000 cells/mm3 and
falling,
temperatureP 38.0 C
P2 occasions in 24 h, or
once P38.5 C
History of BMT 458 714 Mean 7 y (range 1 m to
17.9 y: derivation set)
Low risk < 4. Mid risk = 4.
High riskP 4. Advanced
stage of disease = 3 points,
Comorbidity = 2 points,
Bacteraemia = 1 point
Death
and validation of
‘Paganini rule’
523 806 Mean 7.1 y (range 1 m to
17.5 y: validation set)
Rackoff rule
Rackoff (1996) Derivation of
‘Rackoff rule’
Indianapolis, USA
(1994–1995)
ANC < 500 cells/mm3,
temperature >38.0 C
P3 occasions inP 24 h,
or once >38.5 C.
Outpatient status
72 115 Range 9 ms to 18 y:
derivation set
Low risk = AMC > 100; Mid
risk = AMC < 100, and
temp < 39; High
risk = AMC < 100, but
tempP 39
Bacteraemia
Clinical reason for admission
Rackoff (1996) Revision of
‘Rackoff rule’
(1993) 57 Validation set not
reported
Low risk = AMC > 100
Baorto (2001) Validation/
recalibration of
‘revised Rackoff
rule’
St. Louis, Dallas
and Houston, USA
(1990–1996)
ANC < 500 cells/mm3,
temperatureP 38 C,
12 m or older
History of BMT 558 1171 Mean 8.0 y (range 1–
23 y)
Low risk = AMC > 100 Bacteraemia
ICU/Death related to
bacteraemia within 72 h of
admission for FN
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E
U
R
O
P
E
A
N
JO
U
R
N
A
L
O
F
C
A
N
C
E
R
4
6
(2
0
1
0
)
2
9
5
0
–
2
9
6
4
2
9
5
5
Table 1 – (Continued)
Citation Derivation or
validation study
Study location
(years)
Inclusion criteria Exclusion criteria Total number
of patients
Total number
of episodes
Age of patients Clinical prediction rulea Outcomes
Klaassen (2000) Derivation Toronto, Canada
(1996–1998)
ANC < 500 cells/mm3 or
61000 cells/mm3 and
falling.
Temperature > 38.0 C
P2 occasions inP 12 h,
or once >38.5 C, or
localised infection
New malignant
diagnosis; bone
marrow or stem-
cell
transplantation in
preceding 6 m.
Another medical
condition that
independently
required inpatient
observation.
Interstitial
infiltrate or lobar
consolidation on
chest X-ray
140 227 Median 6.8 y (range 6 m
to 17 y: derivation set)
Low risk = AMC > 100;
Mid risk = AMC < 100,
and temp 6 39; High
risk = AMC < 100, but
temp > 39
Bacteraemia
Significant bacterial
infection (defined as any
blood or urine culture
positive for bacteria,
interstitial or lobar
consolidation on CXR, or
unexpected death from
infection before ANC
recovery (>0.5 · 109/L))
and validation of
CDR (‘Rackoff rule’)
Unclear Unclear 136 Median 7.6 y (range 1–
18 y: validation set)
Madsen (2002) Validation/
recalibration of
‘Rackoff rule’
Indianapolis, USA
(1997)
New admissions ‘coded’
as ‘fever of unknown
origin’ and
ANC < 500 cells/mm3
History of BMT.
AML. In-patient
status
76 157 Mean 8 y (range 2 m to
18 y)
Low risk = AMC > 100;
Mid risk = AMC < 100,
and temp < 39; High
risk = AMC < 100, but
tempP 39
Positive blood culture
Tezcan (2006) Validation of
‘Rackoff rule’
Antalya, Turkey
(1996–2004)
ANC 6 500 cells/mm3 or
61000 cells/mm3 and
falling, axilliary
temperature P38.0 C
P2 occasions at 4 h
intervals, or once
>38.3 C
Fever that occurred
following
transfusion of
blood and blood
products or
administration of
G-CSF
240 621 Median 6 y (range 2 m
17 y)
Low risk = AMC > 100 Death
Clinically suspected
infection
Microbiologically
documented infection
Santolaya rule
Santolaya (2001) Derivation of
‘Santolaya rule’
5 centres in
Santiago, Chile
(1996–1997)
ANC 6 500 cells/mm3,
axilliary temperature
P38.0 CP 2 occasions
1 h apart, or once
P38.5 C
Not reported 257 447 Mean 7 y (range 6 m to
18 y)
Low risk = 0 factors or
isolated low plts or <7 d
from chemotherapy.
High risk = >1 risk factor,
or isolated high CRP,
hypotension or relapsed
leukaemia. Risk factors:
CRPP 90, hypotension,
relapsed leukaemia, plts
650, chemotherapy
within 7 d
Invasive bacterial infection
(positive blood culture – 2 for
CoNS, positive bacterial
culture from usually sterile
site, or sepsis syndrome and/
or focal organ involvement
and haemodynamic
instability and severe
malaise)
Death
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the spectrum of classification.
3.2. Techniques of CDR derivation
The 16 reports of attempts to derive a CDR varied in the pop-
ulations included the predictor variables and adverse out-
comes they reported. The model-building technique, the
reporting and handling of missing data and multiple-episode
data and the use and categorisation of continuous and cate-
gorical variables were also assessed. Details are available in
Web Appendices 4 and 5.
3.3. CDR performance
The CDR had diverse test performance (see Table 2 for detail).
This heterogeneity has largely been explored using a narra-
tive structure, as pooling across all the studies was not possi-
ble due to the varied rules, outcomes and populations
studied. It was examined by analysis of the tabulated CDR
performance data and graphically with plots of sensitivity
and specificity (Web Fig. 1 for unpooled studies and Figs. 2
and 3 for pooled studies).
Meta-analysis of studies which used identical CDR was
undertaken in two cases: the ‘Rackoff rule’36 to examine bac-
teraemia,22,26,28,34,36 and the ‘Santolaya rule’ for serious infec-
tious complications.32,33
The ‘Rackoff rule’ discriminates between three groups of
individuals at low, moderate and high risk of bacteraemia. A
study which reported ‘microbiologically documented infec-
tion’ rather than the narrower ‘bacteraemia’ appeared as a
significant outlier (see Fig. 2a).34 Exclusion of this study led
to a more Normal distribution of the posterior probability
plots. Undertaking a sensitivity analysis by exclusion of the
initial rule derivation study demonstrated poorer discrimina-
tory ability (see Fig. 2b for a ‘best estimate’ summary) LR
[low] = 0.22 (95% CrI 0.03–1.85), LR [medium] = 0.79 (95% CrI
0.12–2.06) and LR [high] = 3.41 (95% CrI 0.24–18.7). The proba-
bility of bacteraemia in each of these groups will vary with
the baseline chance of bacteraemia. If we use a 22% overall
prevalence of bacteraemia (the average proportion over the
included studies which report these data) the predictive val-
ues are; Low risk = 6% (95% CrI 1–34%), Mid risk = 18% (CrI 3–
37%) and High risk = 49% (95% CrI 6–84%).
The ‘Santolaya rule’ showed a moderate ability to differen-
tiate between low- and high risk groups considering the out-
come of ‘invasive bacterial infection’. The derivation sample
performed marginally less effectively than the validation
set. The pooled estimate of test accuracy is LR [low] = 0.17
(95% CI 0.12–0.23) and LR [high] = 2.87 (95% CI 2.43–3.38), see
Fig. 3. Using the average ‘invasive bacterial infection’ rate of
47%, this leads to the probability of ‘invasive bacterial infec-
tion’ in the low group as 13% (95% CI 9–13%) and 72% (95%
CI 68–75%) in the high group. The two studies examining this
rule are from the same research group (although in a multi-
centre study environment) and the rule has not been subject
to further validation.
Assessments of potential sources of heterogeneity showed
that derivation studies generally had better accuracy than
validation studies. The outcome studied also appeared to
Table 2 – Predictive performance of clinical decision rules.
Citation Clinical prediction rule Number in study Outcome Number with outcome Predictive accuracy
% Low LR Low LR High
Models with one supporting dataset
Adcock (1999) High risk = hypotension/septic
shock, inflamed central line site,
recent high dose Ara-C
33 Gram-positive
bacteraemia
6 Data not given
Alexander (2002) Low risk = Nnt AML/Burkitts/
Induction ALL/Progressive-
relapsed with marrow
involvement and no significant
comorbidity
104 Bacteraemia 13 58%* 0.24 2.39
Ammann (2003)
(model #1:
bootstrapped)
Final decision tree model: four
covariates were used to classify
low risk; bone marrow
involvement, leucocyte
count > 0.5 · 109/L, with clinical
signs of a viral infection, and aged
up to 6 years at presentation. For
those with a leucocyte
count 6 0.5 · 109/L, they were
further classified according to CRP
level (6 or >50 mg/L)
111 Severe bacterial
infection, (death from
bacterial infection, a
positive culture of
normally sterile body
fluids, radiologically
proven pneumonia,
clinically unequivocal
diagnosis of a bacterial
infection, or
CRP > 150 mg/L)
90 10% 0 1.18
(model #2) Low risk 6 3 factors. Risk
factors = bone marrow
involvement, absence of clinical
signs of viral infection, high
serum CRP level, low leucocyte
count, presence of a central
venous catheter, high
haemoglobin level, and Pre-B-cell
leukaemia
(111) As above (90) 14% 0 1.29
(model #3) Low risk 6 4 factors. Risk
factors = bone marrow
involvement, absence of clinical
signs of viral infection, high
serum CRP level, low leucocyte
count, presence of a central
venous catheter, high
haemoglobin level, and Pre-B-cell
leukaemia
(111) As above (90) 20% 0.07 1.39
Ammann (2004) Low risk = all of: maximum
temp 6 39.7 C, no comorbidity
requiring hospitalisation,
leucocyte count > 0.5 · 109/L, and
in partial or complete remission
132 Bacteraemia 85 26% 0.15 1.40
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Table 2 – (Continued)
Citation Clinical prediction rule Number in study Outcome Number with outcome Predictive accuracy
% Low LR Low LR High
Gala-Peralta
(2005)
Low risk 6 2 of: <1 year, poor
bone marrow response (plt < 75,
ANC < 100),uncontrolled solid
tumour or relapsed leukaemia,
chemotherapy <10 d earlier,
rapid neutropaenia, cardiac and
renal dysfunction
30 Positive blood culture 16 27% 0.18 1.44
Jones (1996) Low risk = ANCP 200,
outpatient at onset, in remission
127 Bacteraemia 68 17% 0.71 1.07
Lucas (1996) Low risk = no chills,
hypotension, or a requirement
for fluid resuscitation at
admission
509 Positive blood culture 82 87% 0.72 4.05
Petrelli (1991) Low risk: patients with solid
tumours and lymphomas stages
I and II. High risk: patients with
leukaemias and lymphomas
stages III and IV,
146 Positive blood culture 35 45% 0.58 1.42
Rondinelli
(2006)
Low risk = 2.5–5 points:
Intermediate risk = 5.5–9 points:
High risk = greater than 9 points
4.5 points for: clinical site of
infection; 2.5 points for: no URTI;
2 points for: CVC; 1 point for:
aged 65 years, fever >38.5 C, Hb
67 g/dL
283 ‘Serious infectious
complication’ – sepsis,
shock, +ve blood cultures,
infection-related death
93 Odds ratio only: Low 1.0
Mid 13
High 50
West (2004)
(bootstrapped)
High risk = temp > 39.5 C and
CRT > 3 s; Mid
risk = temp > 39.5 C or CRT > 3s;
Low risk = neither
143 Requirement for critical care
within 24 h of presentation
(fluid bolusesP 60 ml/kg,
inotropes or ventilation)
36 Low 89% 0.73 Infinite
Mid 10% 2.70
Models with >1 supporting dataset
Santolaya rule
Clinical prediction rule Number in study Outcome Number with Outcome % Low LR Low LR High
Santolaya
(2001)
Low risk = 0 factors or isolated
low plts or <7 d from
chemotherapy. High risk = >1
risk factor, or isolated high CRP,
hypotension or relapsed
leukaemia. Risk factors:
CRPP 90, hypotension, relapsed
leukaemia, plts 6 50,
chemotherapy within 7 d
407 Invasive bacterial
infection = positive blood
culture (2 for Coagulase-
negative Staphylococcus spp),
positive bacterial culture
from usually sterile site, or
sepsis syndrome and/or focal
organ involvement and
haemodynamic instability
and severe malaise
178 42% 0.22 2.41
(continued on next page)
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Table 2 – (Continued)
Clinical prediction
rule
Number in study Outcome Number with O tcome % Low LR Low LR High
Santolaya
(2002)
As above 263 As above 140 40% 0.11 3.91
Rackoff dichotomous rule
Rackoff (1996)
(proposed
from
validation set)
Low risk = AMC > 100;
High risk = AMC < 100
57 Bacteraemia 10 23% 0 1.45
Baorto (2001) As above 1171 Bacteraemia 189 21% 0.45 1.45
Tezcan (2006) As above 671 Microbiological documented infection 225 58% 0.70 1.60
Clinical prediction
rule
Number in study Outcome Number with Outcome % w % Mid LR Low LR Mid LR High
Paganini rule
Paganini (2007) Low risk < 4. Mid
risk = 4. High
risk = >4. Advanced
stage of disease = 3
points,
Comorbidity = 2
points,
Bacteraemia = 1 point
Death 18 82% 10% 0 2.38 12.0
(validation set) As above 806 Death 19 82% 12% 0.12 2.76 9.86
Rackoff three-category rule
Rackoff (1996)
(derivation set) Low risk = AMC > 100;
Mid risk = AMC < 100,
and temp < 39; High
risk = AMC < 100, but
tempP 39
115 Bacteraemia 24 17% 65% 0 0.87 3.44
(validation set) As above 57 Bacteraemia 10 23% 40% 0 0.21 3.52
Klaassen (2000) As above 226 Bacteraemia 28 37% 37% 0.35 0.75 2.57
Significant bacterial infection 43 0.39 0.94 2.29
(validation set) As above 136 Bacteraemia 28 42% 33% 0.21 4.34 3.09
Significant bacterial infection 26 0.59 1.28 1.41
Madsen (2002) As above 157 Bacteraemia 12 25% 64% 0.31 0.91 3.72
ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; AMC, absolute monocyte count; CoNS, coagulase-negative Staphylococcus; C , C-reactive protein; CRT, capillary refill time; CXR,
chest X-ray; Hb, haemoglobin. Plt, platelet.
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Fig. 2 – (a) Results of the individual ‘Rackoff’ CDR studies. The ROC space plots show each study estimates of sensitivity and
specificity as a marker at the point estimate, with 95% confidence intervals demonstrated by lines. In reading such graphs,
tests with a better discriminatory ability fall in the top left corner of the plot, and non-discriminatory tests fall on a 45 line
between the bottom left and top right. The dashed lines (light blue)/circles represent the dichotomy of low and medium
versus high risk groups (5 datasets), the solid lines (darker blue)/triangles between low versus medium and high (7 datasets).
The outlier (32) is towards the centre of the graph. (b) Pooled results of the ‘Rackoff’ CDR meta-analysis. The dashed lines
(light blue)/circles represent the dichotomy of low and medium versus high risk groups (4 datasets), the solid lines (darker
blue)/triangles between low versus medium and high (5 datasets). The meta-analytic summary estimates are shown in
heavy lines (black)/squares. (For interpretation of the references to colour in this figure legend, the reader is referred to the
web version of this article.)
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Fig. 3 – Pooled and individual results of the ‘Santolaya’ CDR
studies. The dashed lines (light blue)/circles represent the
individual studies. The meta-analytic summary estimates
are shown in heavy lines (black)/squares. (For interpretation
of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
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populations make this difficult to examine clearly. ThoseCDRs developed in a population where the highest risk pa-
tients are excluded (e.g. bone marrow transplant recipients)
did not seem to differ from rules developed without these
exclusions. All these analyses are confounded by the correla-
tion of location, population, outcome and rule. For example:
the Santolaya studies took place in Chile, excluded BMT,
looked at a broad definition of infectious complications and
developed a 5-item rule, the Rackoff model was developed
in the United States, did not clearly exclude any patient
group, primarily examined bacteraemia and produced a rule
based on a single haematological parameter and temperature.
Examination of the detailed content of all the proposed
rules shows they address four major domains (Web Appendix
6). The first can be considered stable patient-related factors,
including age and the underlying disease. The second group
reflects treatment; the presence of a central venous catheter
and the type or duration since last chemotherapy. The third
group reflects episode-specific clinical features, such as max-
imum temperature, the patient’s blood pressure or clinical
features of infection. The final group contains episode-spe-
cific laboratory test values. These are various markers of bone
marrow function where, excepting,23 each rule uses a single
item which reflects one of the three major cellular compo-
nents: haemoglobin, platelets, leucocytes (or a subset);
and serum inflammatory markers (C-reactive protein). An
exploratory analysis of the individual features common
across predictive studies shows that age, malignant disease
state, clinical assessments of circulatory and respiratory
2962 E U R O P E A N J O U R N A L O F C A N C E R 4 6 ( 2 0 1 0 ) 2 9 5 0 –2 9 6 4compromise, higher temperatures and bone marrow suppres-
sion all have some explanatory power.
4. Discussion
This is to our knowledge the first systematic review andmeta-
analysis of risk prediction rules in paediatric febrile neutro-
paenia. It describes 20 studies producing 16 separate models,
assessing a variety of outcomes, with individual differences
in definitions, covering five main categories: death, critical
care requirement, serious medical complication, significant
bacterial infection and bacteraemia. Despite the inclusion of
nearly 8000 episodes of FNP, this review cannot conclude that
any system is more effective or reliable than any other.
A clinical decision rule for febrile neutropaenic episodes
can be broadly considered to have two uses. Primarily it is
to decide if the risk of an episode is ‘low enough’ to allow re-
duced intensity therapy (e.g. outpatient management), but at
the opposite end of the risk scale, a CDR may be helpful to di-
rect increasingly close observation and more aggressive man-
agement. The patients at ‘high risk’ do not have such clear
management options: there are no effective truly prophylac-
tic measures to prevent sepsis syndrome but early recognition
may prevent progression to septic shock.39
The majority of CDR in this review focus upon defining a
group at ‘low risk’ of complications. Two rules in particular
have been subject to greater verification, other rules show
promise and have clinical/physiological similarities, but have
had less validation.
The performance of only one rule could be reasonably as-
sessed across multiple datasets; that of absolute monocyte
count and temperature criteria proposed by Rackoff36 to ex-
clude bacteraemia. This CDR, tested in 1171 episodes over five
datasets, in three different groups across time and in different
centres, has the greatest strength of evidence. The most
appropriate pooled estimate of the rule’s effectiveness shows
limited discriminatory ability, LR [low] = 0.22 (95% CrI 0.03–
1.85), LR [medium] = 0.79 (95% CrI 0.12–2.06) and LR
[high] = 3.41 (95% CrI 0.24–18.7). The marked uncertainty in
these estimates is best demonstrated by the post-test proba-
bilities of bacteraemia: Low risk = 6% (95% CrI 1–34%), Mid
risk = 18% (CrI 3–37%) and High risk = 49% (95% CrI 6–84%).
Of the other rules the Santolaya model33 shows a moder-
ate ability to differentiate between groups at low and high risk
of ‘serious infection’, but again with marked uncertainty (LR
[low] = 0.17 (95% CI 0.12–0.23) and LR [high] = 2.87 (95% CI
2.43–3.38), post-test probabilities for the low risk group = 13%
(95% CI 9–13%) and in the high risk group 72% (95% CI 68–
75%)). The rule has been developed and tested in Chile, which
may limit its applicability inWestern Europe and North Amer-
ica. The proportion of patients with bacteraemia (25%) is
similar to the other studies in this review, but their broad def-
inition of adverse medical outcomes, as found in 50% of
cases, does not have a direct comparator among the Western
European/North American studies reviewed, therefore no
accurate conclusion can be reached. This reflects an uncer-
tainty in the selection of the desired and measurable out-
come. An ideal study would consider not just death, critical
care requirement, serious medical complication, significantbacterial infection or bacteraemia but ‘an absence of adverse
consequences’.
Any adaptation or development of a new rule should pri-
marily look to assess the variables shown in themany CDR re-
viewed to be of predictive value, over those found purely by
‘p-value’ sampling of bivariable testing. In addition to reduc-
ing random error, building upwards from the simple clinical
variables of age, disease and basic clinical examination will
ensure any complex tests add significant value to the funda-
mentals of patient assessment.
An analysis of the techniques used to build the CDR was
incorporated into this review. The studies are spread across
a number of years, and during that time there have been sig-
nificant methodological developments and technological
improvements which have made previously complex compu-
tation within the reach of many health researchers. However,
a series of previously described methodological problems
with diagnostic/prognostic model papers were present in this
review. These included: small event-per-variable ratios lead-
ing to models more likely to be overfitted to their original
dataset and disappointing in clinical practice40; overestima-
tion of accuracy from derivation studies; failure to examine
for non-linear relationships, which may misjudge a predictor
as unimportant,41 for example, there are plausible reasons to
assume that patient age may have a non-linear ‘U’-shaped
relationship with infection and outcome,42 as should time-
from-chemotherapy; use of data-driven stepwise variable
selection and cutpoint determination techniques which may
give spurious results43,44; premature categorisation of contin-
uous data; lack of examination of missing data and subopti-
mal examination of clustered data.
This review has demonstrated a wide range of rules for the
prediction of adverse outcomes during episodes of febrile
neutropaenia in children. None of the rules identified has
been subject to the extensive geographical and temporal dis-
criminatory validity assessments that mark the highest qual-
ity CDRs, and many potential difficulties with model building
have been identified. Practical application of many of these
CDR within an in-patient environment is likely to be safe
but without further research uncertainty will remain as to
the efficiency of the CDR in use. To provide this information
and maximise the value of the information already collected
by these and other cohorts of children with febrile neutropae-
nia, an individual-patient-data (IPD) meta-analysis is being
undertaken to develop and test new or existing prediction
models and provide a firmer basis for stratified treatment tri-
als in this common and occasionally fatal complication of
therapy.45
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